Jasdeep S Miglani, MD

Verified facts

What the public records show

CMS Open Payments records show Jasdeep S Miglani, MD received $329,056.99 in general payments during 2025 across 432 reported records.

Alkermes, Inc. accounted for 40.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Lybalvi, Uzedy.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Aristada by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lybalvi by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vivitrol by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Uzedy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.